AGP Picks
View all

Oklahoma Business Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Business Journal.

Press releases published on May 30, 2026

Level Home Brings Commercial and Pre-Construction Pier Services to Oklahoma
Level Home Reports Surge in Foam Injection and Crawl Space Repair Demand
Oklahoma Clay Soil Drives Record Foundation Repair Demand in Tulsa
Pier and Beam Repair Demand Rises Across Tulsa's Older Neighborhoods
Level Home Foundation Repair Reaches 179 Five-Star Reviews in Tulsa
Helical Pier Demand Grows as Oklahoma Clay Soil Challenges Builders
Pompa Program Surpasses 1,300 Trustpilot Ratings with 4.7/5 Star Average
Global Times: Chinese artisan weaves Zhuang brocade into World Cup
Global Times: At 80, award winning illustrator Cai Gao still draws inspiration from childhood
FLOW Cryptocurrency Investor News: If You Have Suffered Losses in FLOW Cryptocurrency, You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS
National Champions are Honoured at the Closing Ceremony of the Skills Canada National Competition 2026, in Toronto
Les champions nationaux sont à l'honneur à la cérémonie de clôture des Olympiades canadiennes des métiers et des technologies 2026, à Toronto
UPST DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action – UPST
ThinkCareBelieve:  Week 71 of the Trump Administration 2.0
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia ja edennyt syöpä
Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
AI Sector Growth Accelerates Past $26 Billion as Ruvi AI (RUVI) Launches New Features, Proprietary Models, and Ecosystem Upgrades

Share this page:

Sign up for:

Oklahoma Business Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.